10-Q: eXoZymes Inc. Reports Q1 2025 Results: Net Loss Widens Amid Increased R&D and Administrative Costs

eXoZymes Inc. reports a net loss of $1.86 million for Q1 2025, compared to a $1.01 million loss in Q1 2024, driven by increased operating costs.

Summary

• eXoZymes Inc. reported a net loss of $1,856,421 for the three months ended March 31, 2025, compared to a net loss of $1,008,458 for the same period in 2024.
• The company's total operating income remained at $0 for both periods.
• Operating costs increased significantly, with general and administrative costs rising from $730,876 in Q1 2024 to $1,375,712 in Q1 2025.
• Research and development costs, net of grants, also increased from $277,582 to $575,016.
• The company's cash and cash equivalents decreased from $9,719,310 at the end of 2024 to $8,511,477 as of March 31, 2025.
• The company had 8,367,810 common shares outstanding as of March 31, 2025, and December 31, 2024.
• The company believes it has sufficient working capital for the near term, but there remains substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls and the company's pre-revenue status.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to increased losses, rising operating costs, declining cash reserves, and concerns about the company's ability to continue as a going concern. While there are some positive aspects, such as grant funding, the overall financial situation is concerning.

Positives

• The company received a $283,805 grant from the National Institute of Health (NIH) BioClick in March 2025.
• Interest income increased to $94,307 for the three months ended March 31, 2025, compared to $0 for the same period in 2024.
• The company is actively pursuing additional grants to improve its working capital position.

Negatives

• The company's net loss increased significantly, indicating a worsening financial situation.
• Operating costs are rising sharply, driven by increased compensation, professional fees, and other administrative expenses.
• The company's cash reserves are declining, raising concerns about its ability to fund future operations.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's pre-revenue status and anticipated funding shortfalls pose a significant risk to its long-term viability.
• The company's ability to secure additional financial support is uncertain.
• Economic recession could impact the general business environment and the capital markets, which could affect the company.
• Changes to United States tariff and import/export regulations may have an adverse effect on the company's business, financial condition and results of operations.
• Government action on tariffs and research grants and other funding may impede the company's ability to conduct its research and to raise capital by and for its partner companies and other clients.

Future Outlook

The company intends to continue allocating its available working capital toward advancing its research, development, and commercialization initiatives and may seek additional funding through equity sales, institutional and bank funding, or licensing of intellectual property rights.

Management Comments

• Management believes that eXoZymess technology is a differentiated and unique synthetic biology platform.
• Management believes the platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than the typical methods used today, such as chemical synthesis, natural extraction, and synthetic biology.

Industry Context

eXoZymes operates in the biotechnology industry, specifically focusing on synthetic biology and biomanufacturing. Competitors include companies developing similar cell-free systems for producing chemicals, pharmaceuticals, and other products. The company's success depends on its ability to develop and commercialize its technology effectively and efficiently.

Comparison to Industry Standards

• It is difficult to compare eXoZymes directly to industry standards due to its pre-revenue status and unique technology platform.
• Comparable companies in the synthetic biology space, such as Amyris and Ginkgo Bioworks, have faced challenges in achieving profitability despite significant investments and partnerships.
• eXoZymes' reliance on grant funding and its need for additional capital raise concerns about its long-term financial sustainability.

Legal Proceedings

• As of March 31, 2025 and 2024, the Company was not subject to any pending or threatened legal claims or actions.

Related Party Transactions

• As of March 31, 2025, the Company had an outstanding payable of $135,712 to MDB Capital Holdings, LLC.
• The payable is non interest bearing and will be paid in 2025.

Stakeholder Impact

• Shareholders may be concerned about the company's increasing losses and declining cash reserves.
• Employees may be affected by potential funding shortfalls and the company's ability to continue as a going concern.
• Customers and suppliers may be impacted by the company's ability to develop and commercialize its technology.

Next Steps

• The company will continue to allocate its available working capital toward advancing its research, development, and commercialization initiatives.
• The company intends to pursue additional grants from time to time, which if granted to the Company will further improve its working capital position.

Key Dates

Keywords

eXoZymes, financial results, net loss, operating costs, research and development, going concern, biotechnology, synthetic biology, grants, liquidity, capital resources